Sector News

Biogen dubs publicly traded hemophilia spinoff Bioverativ

August 9, 2016
Life sciences

Biogen has fleshed out its plan to spin out its blood disorder products and candidates into a separate publicly traded company. The new co will be known as Bioverativ and is slated to launch in early 2017 and trade on the Nasdaq market.

It will include commercialized hemophilia drugs Eloctate and Alprolix, which are partnered with Swedish Orphan Biovitrum (Sobi), as well as a pipeline including gene therapy programs for hemophilia A and B, a non-factor bispecific antibody program to treat patients with hemophilia A and those with inhibitors, as well as sickle cell disease research.

“We’ve chosen to spin off our growing hemophilia business, because we believe it’s the right decision to ensure fit and focus,” said outgoing Biogen CEO George Scangos on the company’s July earnings call.

He added, “That business continues to perform well, with combined second quarter revenues of over $200 million for Eloctate and Alprolix. Alprolix also was approved by the European Commission for the treatment of hemophilia B and will be commercialized in the EU by our collaboration partner, Sobi.”

Bioverativ will be headed by CEO John Cox, formerly Biogen EVP of Pharmaceutical Operations & Technology. “The new company’s name creates a clear connection to our Biogen heritage and biotech focus,” he said in a statement. Biogen first announced its spinoff plans earlier this year in May.

The new company is expected to use the revenues from the marketed drugs to support continued R&D in blood disorders. Specifically, it hopes to create longer acting therapies based on its XTEN technology and get this into the clinic during the first half of 2017. In addition, it expects to move faster on the development for bispecific antibodies and hemophilia-related gene therapy programs.

Bioverative also plans to conduct clinical testing on Eloctate as a potential means to rapidly induce immune tolerance in hemophilia patients who develop inhibitors.

By Stacy Lawrence

Source: Fierce Biotech

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.